We encountered an unexpected error, we encourage you to try again later.
Should you have additional questions please contact PfizerPro customer service.
Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time
Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.
To gain access please enter your professional information within your account.
Should you need further support updating your account information, please contact PfizerPro customer service.
Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time
Should you have additional questions please contact PfizerPro customer service.
Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time
All samples available online to you are included below. Availability is updated periodically.
Savings cards will be shipped with Product Samples, if applicable.
Use your mouse, finger, or stylus to sign below.
I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.
We have received your order and are getting it ready
Download available co-pay cards and patient savings offers across select Pfizer products.
Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.
Changes you have made will not be saved.
This site is intended for U.S. healthcare professionals.
Menu
Close
Professional Resources
Patient Resources
SOMAVERT Video Library
www.pfizermedicalinformation.com
Search Pfizer’s collection of Medical Response Documents to obtain immediate access to product information. Receive real-time answers to your product questions via your preferred communication channel (chat, email, or phone—available for selected Pfizer products). Submit a Medical Question to be answered by our staff of medical professionals. Registration is required.
Note: The following websites are neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of these sites.
www.aace.com
The AACE professional site, with members only access, certification programs, publications, and resources.
www.endocrine.org
Site for the world’s oldest, largest organization devoted to hormone research and endocrinology.
www.rarediseases.org
Featuring a Rare Disease Database, news, research, conferences, and meetings.
www.pituitarysociety.org
Serves as a source for information about diseases of the pituitary gland. Conducts International Pituitary Congress programs.
AcroTracker, an iPhone® and Android™ app developed by Pfizer, helps your patients track acromegaly symptoms and share them with you. Learn more at www.acrotracker.com, or download the app directly at the iTunes app store.
iPhone is a trademark of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.
Share these resources with your patients who have been diagnosed with acromegaly and are starting on SOMAVERT:
Note: The following websites are neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of these sites.
www.acromegalycommunity.org
This is a support network run by patients for people touched by acromegaly. It offers information on issues such as surgery, medication, radiation, and postdiagnosis support. In addition, it provides a network of emotional support for acromegaly patients, as well as their friends and family.
www.hormone.org
This is the public education affiliate of the Endocrine Society. Its mission is to be a resource for the public by promoting the prevention, treatment, and cure of hormone-related conditions.
www.pituitarysociety.org
This website presents articles on pituitary diseases, information about International Pituitary Congress programs, a glossary of terms, downloadable pdf booklets, and further resources on pituitary-related conditions.
www.pituitary.org
Founded by a group of patients with acromegaly, this is the website of an international nonprofit organization. The PNA is the world's largest patient advocacy organization for people with pituitary tumors and disorders.
www.pituitaryworldnews.org
PWN connects thought leaders to patients and brings up-to-date information on health-related matters of importance to those with pituitary tumors and other pituitary disorders.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2026 Pfizer Inc. All rights reserved.
Patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.
Patients with acromegaly and diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of treatment with SOMAVERT.
Important safety information regarding liver test monitoring
Baseline serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL), and alkaline phosphatase (ALP) levels should be obtained prior to initiating therapy with SOMAVERT. Monitor liver tests based on baseline values and changes during therapy according to the schedule in the full Prescribing Information.
Asymptomatic, transient elevations in transaminases up to 15 times ULN have been observed in <2% of subjects among two open-label trials (with a total of 147 patients). These reports were not associated with an increase in bilirubin. Transaminase elevations normalized with time, most often after suspending treatment. Postmarketing reports have identified elevations in serum hepatic transaminases up to >20 times ULN associated with elevation in total bilirubin >2 times ULN. In many of these cases, discontinuation of SOMAVERT therapy resulted in improvement or resolution of hepatic laboratory abnormalities. If a patient develops liver test elevations, or any other symptoms of liver dysfunction while receiving SOMAVERT, please see Liver Tests section of the full Prescribing Information.
In subjects with systemic hypersensitivity reactions, caution and close monitoring should be exercised when reinitiating SOMAVERT therapy.
The most common adverse events (>6% and at frequencies greater than placebo) in the active treatment arms in a placebo-controlled study (N=112) included infection (23%), pain (14%), nausea (14%), diarrhea (14%), abnormal liver function tests (12%), flu syndrome (12%), and injection-site reaction (11%).
Lipohypertrophy has been reported in patients treated with SOMAVERT; therefore, injection sites should be rotated daily.
SOMAVERT® (pegvisomant for injection) is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-I (IGF-I) levels.
Please see full Prescribing Information.